IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase I drugs for Splenic Marginal Zone B-Cell Lymphoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IC9 CAR.19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IC9 CAR.19 overview
iC9 CAR.19 is under investigation for the treatment of relapsed/refractory b-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, nodal marginal zone B -cell lymphoma, splenic marginal zone B -cell lymphoma, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma), primary mediastinal B-cell lymphoma and mantle cell lymphoma. It is administered through intravenous route. It constitutes chimeric antigen receptor (CAR) T cells which target CD19 protein expressed on cancer cells. AP1903 is administered to activate the iC9-CAR19 safety switch by inducing caspase9 in case of cytokine release syndrome.
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of IC9 CAR.19’s drug-specific PTSR and LoA scores, buy the report here.